- Home
- NBIX vs INCY Comparison
NBIX vs INCY Comparison
Compare NBIX & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- INCY
- Stock Information
- Founded
- NBIX 1992
- INCY 1991
- Country
- NBIX United States
- INCY United States
- Employees
- NBIX N/A
- INCY N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- NBIX Health Care
- INCY Health Care
- Exchange
- NBIX Nasdaq
- INCY Nasdaq
- Market Cap
- NBIX 14.4B
- INCY 17.0B
- IPO Year
- NBIX 1996
- INCY 1993
- Fundamental
- Price
- NBIX $144.07
- INCY $104.20
- Analyst Decision
- NBIX Strong Buy
- INCY Buy
- Analyst Count
- NBIX 18
- INCY 19
- Target Price
- NBIX $172.33
- INCY $89.19
- AVG Volume (30 Days)
- NBIX 1.1M
- INCY 2.7M
- Earning Date
- NBIX 10-28-2025
- INCY 10-28-2025
- Dividend Yield
- NBIX N/A
- INCY N/A
- EPS Growth
- NBIX 12.44
- INCY 3878.02
- EPS
- NBIX 4.19
- INCY 5.90
- Revenue
- NBIX $2,682,700,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- NBIX $23.68
- INCY $19.33
- Revenue Next Year
- NBIX $18.02
- INCY $10.47
- P/E Ratio
- NBIX $34.25
- INCY $17.65
- Revenue Growth
- NBIX 19.61
- INCY 18.09
- 52 Week Low
- NBIX $84.23
- INCY $53.56
- 52 Week High
- NBIX $157.67
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- NBIX 49.83
- INCY 68.08
- Support Level
- NBIX $145.00
- INCY $103.77
- Resistance Level
- NBIX $148.84
- INCY $109.28
- Average True Range (ATR)
- NBIX 5.32
- INCY 4.03
- MACD
- NBIX -0.51
- INCY 0.17
- Stochastic Oscillator
- NBIX 44.39
- INCY 76.16
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.